A Phase 1 Trial of CCI-779 in Combination With EKB-569, an EGFR Inhibitor, in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Pelitinib (Primary) ; Temsirolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Jun 2012 Actual end date changed from Sep 2008 to Oct 2007 as reported by ClinicalTrials.gov.
- 13 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2008 The expected completion date for this trial is now 1 Mar 2005.